Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 1374743-00-6 Chemical Structure| 1374743-00-6

Structure of Trilaciclib
CAS No.: 1374743-00-6

Chemical Structure| 1374743-00-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Trilaciclib is a CDK4/6 inhibitor, with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively.

Synonyms: G1T28; G1T28-1

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Trilaciclib

CAS No. :1374743-00-6
Formula : C24H30N8O
M.W : 446.55
SMILES Code : O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C)CC6)C=C5)N=C43)CCCCC2
Synonyms :
G1T28; G1T28-1
English Name :2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
MDL No. :MFCD30747890

Safety of Trilaciclib

Related Pathways of Trilaciclib

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
NCI-H929 0.72 µM (IC50) 72 hours Evaluate the effect of Trilaciclib on NCI-H929 cell viability, IC50 was 0.72 μM Mol Cell Proteomics. 2024 Jun;23(6):100778
MOLT-4 1.56 µM (IC50) 72 hours Evaluate the effect of Trilaciclib on MOLT-4 cell viability, IC50 was 1.56 μM Mol Cell Proteomics. 2024 Jun;23(6):100778
U937 1.77 µM (IC50) 72 hours Evaluate the effect of Trilaciclib on U937 cell viability, IC50 was 1.77 μM Mol Cell Proteomics. 2024 Jun;23(6):100778
JURKAT 2.97 µM (IC50) 72 hours Evaluate the effect of Trilaciclib on JURKAT cell viability, IC50 was 2.97 μM Mol Cell Proteomics. 2024 Jun;23(6):100778
K562 10 µM 72 hours Evaluate the effect of Trilaciclib on K562 cell viability, results showed more than 70% of cells remained alive Mol Cell Proteomics. 2024 Jun;23(6):100778

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice 5-fluorouracil (5FU)-induced myelosuppression model Intraperitoneal injection 50 or 100 mg/kg Administered 12 hours before each 5FU treatment To evaluate the protective effect of G1T28 against 5FU-induced bone marrow exhaustion, results showed G1T28 pretreatment significantly improved survival and accelerated recovery of peripheral blood counts. Sci Transl Med. 2017 Apr 26;9(387):eaal3986

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06714266 Head and Neck Squamous Cell Ca... More >>rcinoma (HNSCC) Less << PHASE2 NOT_YET_RECRUITING 2026-12-31 -
NCT04504513 Myelosuppression Adult|Chemoth... More >>erapeutic Toxicity|Small Cell Lung Cancer Less << APPROVED_FOR_MARKETING - -
NCT06490081 Myelosuppression PHASE2 RECRUITING 2026-06-30 Cancer Hospital Chinese Academ... More >>y of Medical Sciences, Beijing, Beijing, 100021, China Less <<
NCT06217003 Osteosarcoma PHASE2 NOT_YET_RECRUITING 2025-08-01 The First Affiliated Hospital ... More >>of Xinxiang Medical University, Xinxiang, Henan, 453100, China Less <<
NCT05071703 Extensive-stage Small-cell Lun... More >>g Cancer Less << PHASE4 COMPLETED 2022-11-30 Hainan General Hospital, Haiko... More >>u, Hainan, 100021, China Less <<
NCT06370416 Non-small Cell Lung Cancer PHASE2 NOT_YET_RECRUITING 2025-12-31 Henan Tumor Hospital, Zhengzho... More >>u, Henan, 450000, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.24mL

0.45mL

0.22mL

11.20mL

2.24mL

1.12mL

22.39mL

4.48mL

2.24mL

 

Historical Records

Categories